Back to Results

Pharvaris NV (PHVS)

Pharvaris N.V. is a late-stage biopharmaceutical company focused on therapies for rare diseases with unmet medical needs, particularly conditions driven by bradykinin, including angioedema. Its main development candidate is deucrictibant, a small-molecule bradykinin B2-receptor antagonist being studied for attacks linked to bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1-inhibitor deficiency. The program is in phase 3 development, including studies for both treatment and prevention of hereditary angioedema attacks. Pharvaris is also developing extended-release tablet and immediate-release capsule formulations of deucrictibant. The company was incorporated in 2015 and is headquartered in Zug, Switzerland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PHVS
$36.54
7.4% Upside
Fair
$47.21
38.8% Upside
Undervalued
Fair
—
—
—
0.0%
August 19, 2026
-12.3x
8.8x
—
2.344 B
2.108 B
0.0%
61.6%
7.5
—
87.5%
Send a message
Valuation • Fair Value

Pharvaris NV (NASDAQ-PHVS) Fair Value by Valuation Model

Compare the primary fair value estimate for Pharvaris NV (NASDAQ-PHVS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$36.54

Estimated upside of 7.4% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$41.86

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$29.89

Comparable-company valuation reference.

Analyst Price Target

$47.21

Analysts imply upside of 38.8%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Pharvaris NV (NASDAQ-PHVS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Pharvaris NV (NASDAQ-PHVS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-198.5 M

Current operating profitability reference.

EBITDA Forecast

-222.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Pharvaris NV (NASDAQ-PHVS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Pharvaris NV (NASDAQ-PHVS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

7.5

Relatively strong balance-sheet zone.

FCF / Net Income

87.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Pharvaris NV (NASDAQ-PHVS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Pharvaris NV (NASDAQ-PHVS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 19, 2026

Days to Earnings

29

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Pharvaris NV (NASDAQ-PHVS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Pharvaris NV (NASDAQ-PHVS) Stock Forecast & Technical Outlook

Review Pharvaris NV (NASDAQ-PHVS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Pharvaris NV (NASDAQ-PHVS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Pharvaris NV (NASDAQ-PHVS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Pharvaris NV (NASDAQ-PHVS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Pharvaris NV (NASDAQ-PHVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Pharvaris NV (NASDAQ-PHVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Pharvaris NV (NASDAQ-PHVS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Pharvaris NV (NASDAQ-PHVS) has a Strong Buy consensus, with 10 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 10
Hold 1
Sell 0
FAQ • Fast Investor Answers

Pharvaris NV (NASDAQ-PHVS) Stock FAQ

Quick answers about Pharvaris NV (NASDAQ-PHVS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$36.54
Estimated upside 7.4%
Valuation Rating
Undervalued
Estimated upside of 7.4%
Analyst Target
$47.21
Implied upside 38.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Pharvaris NV (NASDAQ-PHVS) is $36.54. This implies an estimated upside of 7.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 7.4% versus the current market price.

The available analyst price target for Pharvaris NV (NASDAQ-PHVS) is $47.21. The analyst target implies estimated upside of 38.8%.

The current financial health read for Pharvaris NV (NASDAQ-PHVS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Pharvaris NV (NASDAQ-PHVS) is August 19, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Pharvaris NV (NASDAQ-PHVS) is -12.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Pharvaris NV is 2.344 B.

The current enterprise value listed for Pharvaris NV is 2.108 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Pharvaris NV is NASDAQ-PHVS, and the stock is listed on NASDAQ.

Pharvaris NV (NASDAQ-PHVS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Pharvaris NV is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Pharvaris NV is 61.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)